These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 8149364)

  • 1. Apomorphine increases blood glucose concentrations in Parkinson's disease.
    Tison F; Fouillet N; Henry P
    Clin Neuropharmacol; 1994 Feb; 17(1):92-5. PubMed ID: 8149364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The apomorphine test for diagnosis of parkinsonian syndrome].
    Piccini P; Del Dotto P; Napolitano A; Pardini C; Bonuccelli U
    Riv Neurol; 1990; 60(6):221-3. PubMed ID: 2100046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of apomorphine in Parkinson's disease.
    Stocchi F
    Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the clinical pharmacology of Parkinson's disease.
    Montastruc JL
    Therapie; 1991; 46(4):293-303. PubMed ID: 1683024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apomorphine-induced penile erections in Parkinson's disease.
    O'Sullivan JD; Hughes AJ
    Mov Disord; 1998 May; 13(3):536-9. PubMed ID: 9613749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response.
    Maggio R; Barbier P; Corsini GU
    J Neural Transm Suppl; 1995; 45():133-6. PubMed ID: 8748618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DA agonists -- non-ergot derivatives: apomorphine: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S83-9. PubMed ID: 12211146
    [No Abstract]   [Full Text] [Related]  

  • 9. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease.
    Priano L; Albani G; Brioschi A; Calderoni S; Lopiano L; Rizzone M; Cavalli R; Gasco MR; Scaglione F; Fraschini F; Bergamasco B; Mauro A
    Mov Disord; 2004 Aug; 19(8):937-42. PubMed ID: 15300660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine.
    Kempster PA; Lees AJ; Crichton P; Frankel JP; Shorvon P
    Mov Disord; 1989; 4(1):47-52. PubMed ID: 2927402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apomorphine test for dopaminergic responsiveness: a dose assessment study.
    Bonuccelli U; Piccini P; Del Dotto P; Rossi G; Corsini GU; Muratorio A
    Mov Disord; 1993 Apr; 8(2):158-64. PubMed ID: 8474482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The short-duration response to apomorphine: implications for the mechanism of dopaminergic effects in parkinsonism.
    Gancher ST; Woodward WR; Gliessman P; Boucher B; Nutt JG
    Ann Neurol; 1990 Jun; 27(6):660-5. PubMed ID: 2360803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of apomorphine on the bladder of parkinsonian patients].
    Aranda B; Cramer P; Adba MA
    J Urol (Paris); 1992; 98(1):25-9. PubMed ID: 1527394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease.
    Di Rosa AE; Epifanio A; Antonini A; Stocchi F; Martino G; Di Blasi L; Tetto A; Basile G; Imbesi D; La Spina P; Di Raimondo G; Morgante L
    Neurol Sci; 2003 Oct; 24(3):174-5. PubMed ID: 14598073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relief of akinesia by apomorphine and cerebral metabolic changes in Parkinson's disease.
    Broussolle E; Cinotti L; Pollak P; Landais P; Le Bars D; Galy G; Lavenne F; Khalfallah Y; Chazot G; Mauguière F
    Mov Disord; 1993 Oct; 8(4):459-62. PubMed ID: 8232355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Subcutaneous apomorphine in the treatment of Parkinson's disease].
    Linazasoro G
    Neurologia; 1994 Jan; 9(1):1-3. PubMed ID: 8161461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias.
    Calon F; Dridi M; Hornykiewicz O; Bédard PJ; Rajput AH; Di Paolo T
    Brain; 2004 May; 127(Pt 5):1075-84. PubMed ID: 15033896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine receptor stimulating agonists in the treatment of Parkinson's disease.
    Agid Y; Barroche G; Bonnet AM; Javoy-Agid F; Kato G; Lhermitte F; Pollak P; Signoret JL
    Biomedicine; 1979 Jun; 30(2):67-71. PubMed ID: 383169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.